作者
Delvys Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, E Felip, G Speranza, F De Angelis, M Dómine, SY Cheng, HG Bischoff, N Peled, M Reck, Rina Hui, EB Garon, M Boyer, T Kurata, J Yang, MC Pietanza, F Souza, MC Garassino
发表日期
2021/7/1
期刊
Annals of Oncology
卷号
32
期号
7
页码范围
881-895
出版商
Elsevier
简介
Background
In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) versus placebo plus pemetrexed–platinum. We report updated efficacy outcomes from the protocol-specified final analysis, including outcomes in patients who crossed over to pembrolizumab from pemetrexed–platinum and in patients who completed 35 cycles (∼2 years) of pembrolizumab.
Patients and methods
Eligible patients were randomized 2 : 1 to receive pembrolizumab 200 mg (n = 410) or placebo (n = 206) every 3 weeks (for up to 35 cycles, ∼2 years) plus four cycles of pemetrexed (500 mg/m2) and investigators’ choice of cisplatin (75 mg/m2) or carboplatin (area under …
学术搜索中的文章
D Rodríguez-Abreu, SF Powell, MJ Hochmair… - Annals of Oncology, 2021